


PHARMACEUTICAL 2020

CytomX Therapeutics Inc. Rank 146 of 362







PHARMACEUTICAL 2020

CYTOMX THERAPEUTICS

CytomX Therapeutics Inc. Rank 146 of 362

The relative strengths and weaknesses of CytomX Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CytomX Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 69% points. The greatest weakness of CytomX Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is -114%, being 189% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	303,335
Cost of Goods Sold	0
Intangible Assets	949
Liabilities, Current	85,590
Liabilities, Non-Current	204,579
Other Assets	29,626
Other Compr. Net Income	150
Other Expenses	-427
Other Liabilities	0
Other Net Income	8,230
Property and Equipment	7,372
Research and Development	131,619
Revenues	57,489
Selling, General and Administrative Expense	36,765

Output Variable	Value in 1000 USD
Assets	341,282
Liabilities	290,169
Expenses	167,957
Stockholders Equity	51,113
Net Income	-102,238
Comprehensive Net Income	-102,163
Economic Capital Ratio	-114%